ConvaTec Group PLC (LON:CTEC - Get Free Report) shares hit a new 52-week low on Wednesday . The stock traded as low as GBX 206.20 and last traded at GBX 208.80, with a volume of 9914375 shares. The stock had previously closed at GBX 210.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the stock. Citigroup reiterated an "outperform" rating and set a GBX 315 target price on shares of ConvaTec Group in a research note on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a GBX 315 target price on shares of ConvaTec Group in a research note on Wednesday, April 8th. Stifel Nicolaus reiterated a "buy" rating and set a GBX 315 target price on shares of ConvaTec Group in a research note on Wednesday, March 11th. Berenberg Bank reiterated a "buy" rating and set a GBX 340 target price on shares of ConvaTec Group in a research note on Tuesday, April 21st. Finally, Jefferies Financial Group reiterated a "buy" rating and set a GBX 325 target price on shares of ConvaTec Group in a research note on Friday, April 10th. Nine investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of GBX 319.67.
Read Our Latest Stock Analysis on CTEC
ConvaTec Group Price Performance
The company has a market cap of £4.22 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 0.93 and a beta of 0.78. The company has a current ratio of 1.53, a quick ratio of 0.96 and a debt-to-equity ratio of 106.19. The company's 50 day moving average price is GBX 230.43 and its 200 day moving average price is GBX 233.91.
Insider Activity at ConvaTec Group
In other news, insider Jonny Mason sold 291,149 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of GBX 234, for a total value of £681,288.66. Company insiders own 0.95% of the company's stock.
ConvaTec Group Company Profile
(
Get Free Report)
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ConvaTec Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list.
While ConvaTec Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.